skip to content

Other

Study demonstrates efficacy of EKOS therapy, says BTG

16 June 2017 08:17

BTG has highlighted trial results which showed that patients with post-thrombotic syndrome can be treated safely and effectively with EKOS therapy.

BTG said the results of the ACCESS PTS trial were being presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans, on 14-17 June.

The study found chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can be treated safely and effectively with EKOS therapy.

It said: "The ACCESS PTS protocol using EKOS therapy is now the only treatment regimen proven to significantly reduce the signs and symptoms of PTS and show a significant improvement in quality of life." BTG said the ACCESS PTS study was a multicentre prospective single-arm study of 73 patients with iliofemoral DVT, who met eligibility including a Villalta score of 8 or greater (Villalta score measures the signs and symptoms of PTS), and who had failed three months of conservative therapy.

Patients were treated with anticoagulation drugs followed by EKOS therapy with balloon dilatation. BTG said the study met its primary efficacy endpoint and showed a significant improvement of Villalta scores of 34% at 30 days across 77 limbs treated among the 73 patients with a p-value of <0.0001.

On average, patients treated in the study experienced a symptom reduction from severe down to borderline mild.

The study also showed a 21% improvement in patients' quality of life.

There was one bleeding incident and one PE - meeting the study's safety endpoint.

EKOS vice-president and general manager Matt Stupfel said: "With the ACCESS PTS study, BTG is once again demonstrating our commitment to advancing the treatment of VTE patients.

"Chronic DVT can be both debilitating and life threatening. Until now, most chronic DVT and PTS sufferers had no other treatment options.

"The ACCESS PTS data proves that EKOS therapy is a safe and effective option for treating chronic DVT.

"EKOS is setting the standard for interventional chronic-DVT treatment, getting patients back on their feet and on with their lives."

At 8:17am: (LON:BTG) BTG PLC share price was +7.5p at 680p

Story provided by StockMarketWire.com

Related Company: BTG

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

aew-banner-180x255.jpg

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.